Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dana Stallings

Nurse Practitioner, Family Franklin, VA Nurse Practitioner

NPI 1770021545 CMS profile 10686377

1337 Armory Dr, Franklin, VA 23851

Open in the dashboard

General payments

$224,736

732 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Stallings of Franklin, VA is reported in the CMS Open Payments database as having received $224,736 across 732 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $72,721 163
2024 General $52,868 165
2023 General $55,890 172
2022 General $32,658 129
2021 General $10,599 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Stallings
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Dana Stallings were reported at $72,721. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Dana Stallings Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $10,599 $124 $35–$379 $132
2022 $32,658 $141 $44–$430 $149
2023 $55,890 $154 $49–$476 $160
2024 $52,868 $165 $51–$504 $164
2025 $72,721 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $98,950 286 payments
  2. Lilly USA, LLC $97,961 263 payments
  3. Novo Nordisk Inc $24,496 52 payments
  4. Insulet Corporation $453 11 payments
  5. Corcept Therapeutics $411 9 payments
  6. AstraZeneca Pharmaceuticals LP $328 14 payments
  7. Amgen Inc. $279 12 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $241 20 payments
  9. Janssen Pharmaceuticals, Inc $232 6 payments
  10. Tempus AI, Inc $198 3 payments
  11. Other $1,188 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $170,954 175 payments
  2. Travel and Lodging $28,022 155 payments
  3. Food and Beverage $13,872 394 payments
  4. Consulting Fee $11,840 5 payments
  5. Education $48 3 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $96,093 225 payments
  2. MINIMED 780G $56,213 128 payments
  3. MINIMED 770G $16,357 75 payments
  4. RYBELSUS $12,201 32 payments
  5. Ozempic $9,801 31 payments
  6. InPen $5,305 14 payments
  7. INPEN SMART INSULIN DELIVERY SYSTEM $4,623 21 payments
  8. Minimed 770G System $3,283 17 payments
  9. Omnipod $453 11 payments
  10. Korlym $411 9 payments
  11. Other $4,208 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

3,316

Median for Nurse Practitioner: 389

Drug cost

$2,741,886

Median for Nurse Practitioner: $21,885

Branded share of claims

71.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 426 $754,601
Mounjaro Tirzepatide Brand 307 $564,284
Trulicity Dulaglutide Brand 169 $280,370
Jardiance Empagliflozin Brand 139 $159,546
Kerendia Finerenone Brand 123 $132,449
Humalog Kwikpen U-200 Insulin Lispro Brand 20 $103,200
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 57 $81,343
Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt Brand 80 $80,181
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 47 $71,408
Humalog Insulin Lispro Brand 147 $66,742

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$116,202

Of which drugs: $7,410

Medicare patients

328

Average age 73

Services billed

2,937

167 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 54%
Chronic kidney disease 46%
Ischemic heart disease 38%
Heart failure 24%
Depression 24%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 61 61 $4,909

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $38,069
$38,069 307 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $84
$84 45 —
Repatha
  • Amgen Inc. $46
$46 32 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $39
$39 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $31
$31 123 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

732 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record